



International Equity Fund HISIX

SEMI-ANNUAL SHAREHOLDER REPORT | JUNE 30, 2024

This semi-annual shareholder report contains important information about the International Equity Fund ("Fund") for the period of January 1, 2024, to June 30, 2024. You can find additional information about the Fund at <https://www.homesteadfunds.com/fund-literature/>. You can also request this information by contacting us at 800.258.3030.

What were the Fund costs for the last six months?

(based on a hypothetical \$10,000 investment)

Fund	Cost of a \$10,000 investment	Cost paid as a percentage of a \$10,000 investment
International Equity Fund	\$57	1.15%*

* Annualized.

Management's Discussion of Fund Performance

The Fund returned 0.86% for the six months ended June 30, 2024, trailing its benchmark index, the MSCI EAFE Index, which returned 5.34%.

By sector, poor performing stocks in health care significantly detracted from the Fund's relative returns. Within health care, Japanese biopharma holdings **Chugai Pharmaceutical** and **Shionogi** weighed on returns, with Shionogi disclosing that its candidate weight-loss drug showed less favorable results in clinical trials than currently available treatments, while Chugai shares sagged on a competitor's potential drug to challenge the dominance of Hemlibra, Chugai's hemophilia treatment. **Genmab** lagged on expense worries, although it reported progress on its cancer drugs in the pipeline. Not owning **Novo Nordisk**, the weight-loss drugmaker, hurt relative returns.


Our holdings in information technology also detracted from returns, despite strong performance from **Taiwan Semiconductor**, whose shares continued to soar on sustained demand for AI-related chips for NVIDIA and others. **Dassault Systemes** and **Infineon Technologies** were two of the portfolio's top five detractors in the first half of 2024. Shares of **Infineon** clawed back some of this drop in the second quarter, and **SAP** also rose after the company provided more details about AI features coming to its enterprise management software and suggested cloud customer uptake is accelerating.

Viewed by geography, we had poor relative returns in Japan and Europe, both outside the eurozone and inside the eurozone. Strong performing stocks in Canada and the portfolio's modest exposure to emerging markets, which are not held in the index, contributed to relative performance. In Japan conglomerate **Sony**, stood out as the biggest detractor following the release of its first-quarter results, which revealed PS5 console sales falling short of expectations despite a price reduction aimed at boosting sales. In Canada, financial services and insurance provider **Manulife** was a significant contributor.

Fund Performance

The following graph compares the account values at June 30 of each of the most recent 10 years of a \$10,000 initial investment in the Fund and a broad-based securities market index.

GROWTH OF \$10,000



AVERAGE ANNUAL TOTAL RETURNS	1 Year	5 Years	10 Years
International Equity Fund	5.23%	6.24%	4.67%
International Equity Fund—excluding sales load	5.23%	6.24%	4.67%
MSCI®EAFE®Index	11.54%	6.46%	4.33%

Performance information for the International Equity Fund reflects its performance as an actively managed fund subadvised by Mercator Asset Management through September 14, 2015, as a passively managed portfolio directed by SSGA Funds Management Inc. from September 15, 2015 to January 8, 2016, and after a transition, as an actively managed fund subadvised by Harding Loevner LP from January 15, 2016 to period-end.

The returns reflected in the above table and chart represent past performance, which is no guarantee of future results. The returns do not reflect the deduction of taxes that a shareholder may pay on Fund distributions or the redemption of Fund shares.

To obtain the most recent month-end returns, please visit <https://www.homesteadfunds.com/solutions/performance-prices/> or call 800.258.3030.

Key Fund Statistics

The following table reflects important key statistics as of June 30, 2024.

Fund Net Assets	\$87,315,208
Total Number of Portfolio Holdings	50
Portfolio Turnover	7%

Graphical Representation of Holdings

The tables below reflect the investment diversification and the top 10 holdings of the Fund, shown as a percentage of total investments of the Fund.

COUNTRY DIVERSIFICATION		TOP 10 HOLDINGS	
Japan	16.0%	Shell PLC	4.2%
Germany	12.2%	Manulife Financial Corp.	4.0%
France	9.8%	DBS Group Holdings Ltd.	4.0%
Britain	9.6%	Schneider Electric SE	3.6%
Sweden	9.3%	Allianz SE REG	3.5%
Switzerland	8.5%	Roche Holding AG REG	3.3%
Canada	8.0%	Chugai Pharmaceutical Co., Ltd.	3.3%
Singapore	4.0%	SAP SE ADR	3.2%
Denmark	3.7%	Haleon PLC	3.2%
Spain	3.1%	Banco Bilbao Vizcaya Argentaria SA	3.1%
Taiwan	2.1%	Total	35.4%
Australia	2.1%		
United States of America	2.1%		
Hong Kong	1.8%		
Republic of South Korea	1.5%		
Netherlands	1.3%		
India	1.0%		
China	1.0%		
Russia	0.0%		
Indonesia	0.3		
Short-term and other assets	2.6%		
Total	100.0%		

Availability of Additional Information

You can find additional information about the Fund such as its prospectus, financial information, holdings, statement of additional information and proxy voting information at <https://www.homesteadfunds.com/fund-literature/>. You can also request this information free of charge by contacting us at 800.258.3030.

